A Phase 3 clinical trial (NCT05726227) investigating semaglutide for weight management in children and teenagers with obesity completed its primary data collection on October 15, 2025. This milestone signifies that all data for the study's main endpoints has been gathered, moving the trial closer to analysis and the reporting of results.
Background
Semaglutide is currently being evaluated for its potential to help children and teenagers with excess body weight achieve weight loss. The drug is being studied as an intervention for obesity in this younger population, building on its established role in adult weight management.
Trial design
The study, titled 'A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight' (NCT05726227), is a Phase 3 trial. It has an estimated enrollment of 210 participants diagnosed with obesity. The trial is designed to compare the effect of semaglutide on body weight in children and teenagers against a placebo, or 'dummy' medicine. Participants, along with their parents, receive guidance from study staff on healthy food choices and physical activity. The treatment assignment (semaglutide or placebo) is determined by chance, ensuring a randomized comparison.
What this means
The primary completion of this Phase 3 trial marks a significant step towards understanding the efficacy and safety profile of semaglutide in pediatric obesity. With data collection now complete, the focus shifts to comprehensive data analysis, which will determine how well semaglutide helps children and teenagers lose weight compared to placebo. The findings from this study are anticipated to provide crucial information for clinicians and patient advocates considering treatment strategies for obesity in this vulnerable population.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05726227 was recorded on 2025-10-15 on clinicaltrials.gov.